Tumours of the vagus nerve are rare but clinically significant because the nerve controls heart rate, voice, swallowing, and digestion. Most vagal tumours are benign — schwannomas and paragangliomas account for the large majority — and many are discovered incidentally on imaging. This article covers the tumour types, how they are diagnosed, the treatment options, and what to expect after surgery.
Types of Vagus Nerve Tumours
Vagal schwannomas are the most common tumour of the vagus nerve. They arise from Schwann cells, which produce the myelin sheath that insulates nerve fibres. Schwannomas are almost always benign, grow slowly (typically 1-2 mm per year), and are well-encapsulated, meaning they push the nerve fibres aside rather than infiltrating them. They most frequently appear as a painless neck mass in the parapharyngeal space, presenting between the ages of 30 and 60.
Vagal paragangliomas (glomus vagale tumours) are the second most common vagal tumour. They originate from paraganglia — clusters of neuroendocrine cells associated with the vagus nerve. Paragangliomas are also usually benign but are more vascular than schwannomas and more likely to be locally invasive. Approximately 5 percent are malignant. In roughly 10 percent of cases, vagal paragangliomas are familial, linked to mutations in succinate dehydrogenase (SDH) subunit genes (SDHB, SDHC, SDHD). Patients with hereditary paragangliomas should be screened for synchronous tumours at other sites, including the carotid body and adrenal glands.
Neurofibromas can arise from the vagus nerve, particularly in patients with neurofibromatosis type 1 (NF1). Unlike schwannomas, neurofibromas grow within the nerve fascicles rather than pushing them aside, making complete surgical removal without nerve sacrifice more difficult. Plexiform neurofibromas carry a small risk (5-10 percent) of malignant transformation to malignant peripheral nerve sheath tumour (MPNST).
Malignant tumours of the vagus nerve are rare. They include MPNSTs and, very occasionally, metastatic deposits from cancers elsewhere in the body. Primary vagal malignancies are aggressive and typically require combined surgical and oncological treatment.
Symptoms
Many vagal tumours grow slowly enough that they produce no symptoms for years and are found incidentally on imaging obtained for another reason. When symptoms do develop, they reflect the location and size of the tumour rather than its histological type.
A painless neck mass is the most common presentation. As the tumour enlarges, it can compress or displace the vagus nerve, producing hoarseness (from recurrent laryngeal nerve involvement), dysphagia (difficulty swallowing), a sensation of fullness in the throat, or referred ear pain. Paragangliomas occasionally produce catecholamines, causing episodic hypertension, headache, or palpitations — a presentation that should prompt measurement of urinary catecholamines before any biopsy or surgery.
Cranial nerve deficits beyond the vagus nerve may develop if the tumour extends into the jugular foramen or skull base, potentially affecting the glossopharyngeal nerve (CN IX), accessory nerve (CN XI), or hypoglossal nerve (CN XII).
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
Diagnosis
MRI with gadolinium contrast is the primary imaging modality. Schwannomas appear as well-defined, enhancing masses that displace adjacent structures. Paragangliomas demonstrate a characteristic “salt and pepper” appearance on T1 and T2 sequences due to flow voids from their rich vascular supply. The “lyre sign” — splaying of the internal and external carotid arteries — is a classic angiographic finding in paragangliomas of the vagus nerve that helps distinguish them from carotid body tumours, which sit in the carotid bifurcation itself.
CT angiography or conventional angiography can define the vascular anatomy before surgery. For paragangliomas, functional imaging with 68Ga-DOTATATE PET/CT has largely replaced MIBG scintigraphy for detecting multicentric disease and metastases, offering higher sensitivity and specificity for neuroendocrine tumours.
Fine-needle aspiration biopsy is generally avoided for suspected paragangliomas due to the risk of haemorrhage from their vascularity. For schwannomas, biopsy is rarely needed because the imaging characteristics are usually diagnostic.
Genetic testing for SDH mutations is recommended for all patients with paragangliomas, particularly those under 40, with bilateral tumours, a family history, or extra-adrenal disease.
Treatment
Surgical excision is the standard treatment for symptomatic vagal schwannomas. Because schwannomas are encapsulated and grow eccentrically from the nerve, intracapsular enucleation — removing the tumour from within its capsule while preserving the nerve fibres draped over its surface — can preserve vagal function in a proportion of cases. However, the vagus nerve is sacrificed in approximately 30-50 percent of vagal schwannoma surgeries, depending on tumour size and the degree of nerve involvement.
For small, asymptomatic schwannomas, observation with serial MRI (typically annually, then at longer intervals if growth is slow) is a reasonable strategy, particularly in older patients or those with significant surgical risk. Many of these tumours grow so slowly that they never require intervention.
Vagal paragangliomas are more challenging surgically because of their vascularity and tendency to encase the nerve. Pre-operative embolisation (performed one to two days before surgery) can reduce intraoperative bleeding. The vagus nerve is sacrificed in the majority of paraganglioma surgeries. For patients who are poor surgical candidates or who have bilateral disease, stereotactic radiosurgery (Gamma Knife or CyberKnife) or fractionated radiotherapy can achieve tumour control rates exceeding 90 percent at 10 years, with lower rates of cranial nerve injury compared with surgery.
For malignant vagal tumours, wide surgical excision combined with adjuvant radiation therapy and, in some cases, chemotherapy is the standard approach. Outcomes depend on histological grade, margin status, and the presence of metastatic disease.
Post-Surgical Consequences
When the vagus nerve is sacrificed during tumour removal, the patient will experience unilateral vocal cord paralysis (producing hoarseness and a breathy voice), dysphagia (particularly for thin liquids in the early post-operative period), and reduced pharyngeal sensation on the affected side. Most patients compensate for unilateral vagal loss over weeks to months through contralateral vagal nerve function and learned compensatory swallowing techniques.
Voice rehabilitation may include speech therapy, vocal cord medialisation procedures (injection laryngoplasty or thyroplasty), or a combination. The majority of patients achieve functional voice and swallowing within six months of surgery, although the voice may not return to its pre-operative quality.
Cardiovascular effects of unilateral vagal loss are generally minimal because the contralateral vagus nerve provides sufficient cardiac innervation. Gastrointestinal effects (gastroparesis, reduced gastric acid secretion) are also typically mild after unilateral vagotomy, though some patients report increased bloating or altered bowel habits.
Vagal tumours are one of many conditions that can disrupt the nerve controlling your heart, voice, and digestion. To understand the full anatomy and function of the vagus nerve, the diagnostic pathways, and the treatment options available, the My Vagus Nerve & Me eBook provides a thorough guide. Get My Vagus Nerve & Me eBook and learn how this nerve shapes your health.




